ERBB2 and neoplasm: These small molecules target the intracellular catalytic kinase domain of HER2 and inactivate downstream oncogenic pathways, such as the PI3k/AKT and mitogen-activating protein kinases (MAPK) pathways, ultimately leading to tumor cell death (Figure 1C, Table 1).